Actively Recruiting
Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets
Led by Nurix Therapeutics, Inc. · Updated on 2026-02-05
18
Participants Needed
1
Research Sites
87 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multiple part, multiple cohort study evaluating the relative bioavailability, food effect, and drug-drug interaction of NX-5948 in healthy volunteers.
CONDITIONS
Official Title
Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy adult male or female aged 19 to 55 years
- Non-smoker without nicotine or tobacco use for at least 3 months before dosing
- Body mass index (BMI) between 18.0 and 32.0 kg/m2
- Medically healthy with no significant medical history or abnormal clinical findings
- Able to understand study procedures and willing to comply with the protocol
You will not qualify if you...
- Mentally or legally incapacitated or significant emotional problems
- Significant history or presence of major diseases affecting various body systems
- History of gastrointestinal surgery or gallbladder removal affecting drug absorption
- History or presence of alcohol or drug abuse within the last 2 years
- Allergic reactions or sensitivity to study drugs or related compounds
- Severe allergies or anaphylactic reactions
- Personal or family history of prolonged QT syndrome or sudden cardiac death
- Evidence of certain heart rhythm disorders or use of cardiac pacemaker
- Adrenal insufficiency or skin infections
- Female volunteers of childbearing potential or positive pregnancy test
- Positive tests for HIV, hepatitis B, or hepatitis C
- Blood donation or significant blood loss within 56 days before dosing
- Plasma donation within 7 days before dosing
- Clinically significant medical or psychiatric conditions per investigator
- Previous exposure to NX-5948
- Participation in another clinical study within 30 days or 5 half-lives before dosing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Celerion
Lincoln, Nebraska, United States, 68502
Actively Recruiting
Research Team
A
Angie Badgett, MBA
CONTACT
A
Allen Hunt, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here